Chemical Namebetrixaban
Dosage FormCapsule (oral; 40 mg, 80 mg)
Drug ClassInhibitors
CompanyPortola Pharms Inc.
Approval Year2017


  • For the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Bevyxxa (betrixaban) Prescribing Information2017Portola Pharmaceuticals, Inc. South San Francisco, CA